Jun Takasaki
Jun Takasaki has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Tetsu Saito
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd, 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
2 shared publications Tetsuya Urasaki
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
2 shared publicationsYasuhiko Masuho
2 shared publicationsYasushi Kawauchi
2 shared publications- Haruhiko Ninomiya
From the Division of Hematology, the Institute of Clinical Medicine, and the College of Medical Technology, University of Tsukuba, Tsukuba, Ibaraki, Japan
1 shared publication Hideyuki Tanaka
1 shared publication
Latest Publications
- Open Access
- 1 November 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (46) , 47438-47445
A Novel Gαq/11-selective Inhibitor
- 1 November 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (46) , 47438-47445
Open AccessA Novel Gαq/11-selective Inhibitor
- 1 September 2001
- Published by Elsevier in Molecular Pharmacology
- Vol. 60 (3) , 432-439
Molecular Cloning of the Platelet P2TAC ADP Receptor: Pharmacological Comparison with Another ADP Receptor, the P2Y1 Receptor
- 1 September 2001
- Published by Elsevier in Molecular Pharmacology
- Vol. 60 (3) , 432-439
Molecular Cloning of the Platelet P2TAC ADP Receptor: Pharmacological Comparison with Another ADP Receptor, the P2Y1 Receptor
- 1 January 2001
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 69 (1) , 105-112
Pivotal role of 5-lipoxygenase in the activation of human eosinophils: platelet-activating factor and interleukin-5 induce CD69 on eosinophils through the 5-lipoxygenase pathway
CD69 is an activation-related cell surface molecule on human eosinophils. It has been reported that interleukin (IL)-5, but not platelet-activating factor (PAF), can induce CD69 on human eosinophils in vitro. In this study, PAF induced CD69 intensely on eosinophils from patients with hypereosinophilic syndrome (HES), while only weakly on those from normal donors. Because HES eosinophils contain abundant cytosolic phospholipase A2 (cPLA2) and 5-lipoxygenase (5-LO), we examined the roles of several enzymes involved in the metabolism of arachidonic acid in the PAF- or IL-5-induced CD69 expression on eosinophils. The CD69 expression induced by PAF and IL-5 on HES eosinophils and that by IL-5 on normal eosinophils were both inhibited by AA861 and MK-886, inhibitors of 5-LO activity. In addition, AACOCF3, a selective cPLA2 inhibitor, inhibited IL-5-induced CD69 expression on normal eosinophils, although it hardly affected either IL-5- or PAF-induced CD69 expression on HES eosinophils. Moreover, PAF alone induced CD69 only weakly on normal eosinophils, but exogenous arachidonic acid remarkably enhanced PAF-induced CD69 expression on them. These findings suggest that IL-5 activates both cPLA2 and 5-LO but PAF activates only 5-LO. It is suggested that 5-LO plays a critical role in the induction of CD69 on eosinophils.
- 1 January 2001
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 69 (1) , 105-112
Pivotal role of 5-lipoxygenase in the activation of human eosinophils: platelet-activating factor and interleukin-5 induce CD69 on eosinophils through the 5-lipoxygenase pathway
CD69 is an activation-related cell surface molecule on human eosinophils. It has been reported that interleukin (IL)-5, but not platelet-activating factor (PAF), can induce CD69 on human eosinophils in vitro. In this study, PAF induced CD69 intensely on eosinophils from patients with hypereosinophilic syndrome (HES), while only weakly on those from normal donors. Because HES eosinophils contain abundant cytosolic phospholipase A2 (cPLA2) and 5-lipoxygenase (5-LO), we examined the roles of several enzymes involved in the metabolism of arachidonic acid in the PAF- or IL-5-induced CD69 expression on eosinophils. The CD69 expression induced by PAF and IL-5 on HES eosinophils and that by IL-5 on normal eosinophils were both inhibited by AA861 and MK-886, inhibitors of 5-LO activity. In addition, AACOCF3, a selective cPLA2 inhibitor, inhibited IL-5-induced CD69 expression on normal eosinophils, although it hardly affected either IL-5- or PAF-induced CD69 expression on HES eosinophils. Moreover, PAF alone induced CD69 only weakly on normal eosinophils, but exogenous arachidonic acid remarkably enhanced PAF-induced CD69 expression on them. These findings suggest that IL-5 activates both cPLA2 and 5-LO but PAF activates only 5-LO. It is suggested that 5-LO plays a critical role in the induction of CD69 on eosinophils.
- 1 August 2000
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 274 (2) , 316-322
The Molecular Characterization and Tissue Distribution of the Human Cysteinyl Leukotriene CysLT2 Receptor
- 1 August 2000
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 274 (2) , 316-322
The Molecular Characterization and Tissue Distribution of the Human Cysteinyl Leukotriene CysLT2 Receptor
- 4 December 1998
- Published by Wiley in FEBS Letters
- Vol. 440 (3) , 377-381
Antibodies against type II phospholipase A2 prevent renal injury due to ischemia and reperfusion in rats
This study was performed to determine the involvement of type II phospholipase A2 (PLA2‐II) in renal injury caused by ischemia and reperfusion. Ischemia and reperfusion significantly elevated levels of blood urea nitrogen and serum creatinine in rats. These increases were significantly reduced by i.v. administration of rabbit IgG F(ab′)2 fragments against rat PLA2‐II. Increased levels of acid‐stable PLA2 activity in the kidney were caused by ischemia and reperfusion, and were suppressed by administration of anti‐PLA2‐II F(ab′)2. Increased levels of myeloperoxidase activity, a marker of neutrophil infiltration, in the kidney were also reduced after anti‐PLA2‐II F(ab′)2 treatment. These results suggest that PLA2‐II plays a pivotal role in pathogenesis of ischemia and reperfusion injury through induction of neutrophil infiltration.
- 4 December 1998
- Published by Wiley in FEBS Letters
- Vol. 440 (3) , 377-381
Antibodies against type II phospholipase A2 prevent renal injury due to ischemia and reperfusion in rats
This study was performed to determine the involvement of type II phospholipase A2 (PLA2‐II) in renal injury caused by ischemia and reperfusion. Ischemia and reperfusion significantly elevated levels of blood urea nitrogen and serum creatinine in rats. These increases were significantly reduced by i.v. administration of rabbit IgG F(ab′)2 fragments against rat PLA2‐II. Increased levels of acid‐stable PLA2 activity in the kidney were caused by ischemia and reperfusion, and were suppressed by administration of anti‐PLA2‐II F(ab′)2. Increased levels of myeloperoxidase activity, a marker of neutrophil infiltration, in the kidney were also reduced after anti‐PLA2‐II F(ab′)2 treatment. These results suggest that PLA2‐II plays a pivotal role in pathogenesis of ischemia and reperfusion injury through induction of neutrophil infiltration.
- Open Access
- 15 May 1998
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 160 (10) , 5066-5072
Synergistic Effect of Type II Phospholipase A2 and Platelet-Activating Factor on Mac-1 Surface Expression and Exocytosis of Gelatinase Granules in Human Neutrophils: Evidence for the 5-Lipoxygenase-Dependent Mechanism
Stimulation of human neutrophils with inflammatory mediators such as TNF-α or platelet-activating factor (PAF) induces translocation of adhesion molecule Mac-1 (CD11b/CD18) from secretory vesicles to the plasma membrane. Type II phospholipase A2 (PLA2-II) also induces translocation of Mac-1 from secretory vesicles. However, there are more Mac-1 molecules in gelatinase granules and specific granules than in secretory vesicles. Therefore, different combinations of PLA2-II and other mediators were examined for their ability to induce gelatinase granules and specific granules to induce Mac-1 surface expression. The combination of PLA2-II and PAF synergistically increased Mac-1 surface expression, and the effect was greater than the combinations of PLA2-II with TNF-α, IL-8, or FMLP. Additionally, the combination of PLA2-II and PAF induced exocytosis of both secretory vesicles and gelatinase granules, which did not occur with either PLA2-II alone or PAF alone. The induction was accompanied by marked production of leukotriene B4. AA861, an inhibitor of 5-lipoxygenase, did not inhibit exocytosis of secretory vesicles but did inhibit exocytosis of gelatinase granules and decrease Mac-1 surface expression. It was also found that Ca2+ influx is essential for 5-lipoxygenase activation, because Ni2+, which blocks the influx of extracellular Ca2+, inhibited the production of leukotriene B4. These results suggest that stimulation by the combination of PLA2-II and PAF, unlike stimulation by each mediator alone, causes exocytosis of gelatinase granules via the 5-lipoxygenase pathway, resulting in a synergistic increase in neutrophil Mac-1 surface expression during inflammatory processes.
- 15 May 1998
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 160 (10) , 5066-5072
Open AccessSynergistic Effect of Type II Phospholipase A2 and Platelet-Activating Factor on Mac-1 Surface Expression and Exocytosis of Gelatinase Granules in Human Neutrophils: Evidence for the 5-Lipoxygenase-Dependent Mechanism
Stimulation of human neutrophils with inflammatory mediators such as TNF-α or platelet-activating factor (PAF) induces translocation of adhesion molecule Mac-1 (CD11b/CD18) from secretory vesicles to the plasma membrane. Type II phospholipase A2 (PLA2-II) also induces translocation of Mac-1 from secretory vesicles. However, there are more Mac-1 molecules in gelatinase granules and specific granules than in secretory vesicles. Therefore, different combinations of PLA2-II and other mediators were examined for their ability to induce gelatinase granules and specific granules to induce Mac-1 surface expression. The combination of PLA2-II and PAF synergistically increased Mac-1 surface expression, and the effect was greater than the combinations of PLA2-II with TNF-α, IL-8, or FMLP. Additionally, the combination of PLA2-II and PAF induced exocytosis of both secretory vesicles and gelatinase granules, which did not occur with either PLA2-II alone or PAF alone. The induction was accompanied by marked production of leukotriene B4. AA861, an inhibitor of 5-lipoxygenase, did not inhibit exocytosis of secretory vesicles but did inhibit exocytosis of gelatinase granules and decrease Mac-1 surface expression. It was also found that Ca2+ influx is essential for 5-lipoxygenase activation, because Ni2+, which blocks the influx of extracellular Ca2+, inhibited the production of leukotriene B4. These results suggest that stimulation by the combination of PLA2-II and PAF, unlike stimulation by each mediator alone, causes exocytosis of gelatinase granules via the 5-lipoxygenase pathway, resulting in a synergistic increase in neutrophil Mac-1 surface expression during inflammatory processes.